BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2056 related articles for article (PubMed ID: 24444556)

  • 1. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
    Chen X; Chang Y; Cui HY; Ren CC; Yu BY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free β-hCG and PAPP-A: a 5-year prospective study.
    Ghaffari SR; Tahmasebpour AR; Jamal A; Hantoushzadeh S; Eslamian L; Marsoosi V; Fattahi F; Rajaei M; Niroomanesh S; Borna S; Beigi A; Khazardoost S; Saleh-Gargari S; Rahimi-Sharbaf F; Farrokhi B; Bayani N; Tehrani SE; Shahsavan K; Farzan S; Moossavi S; Ramezanzadeh F; Dastan J; Rafati M
    Ultrasound Obstet Gynecol; 2012 May; 39(5):528-34. PubMed ID: 21793085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the ductus venosus, tricuspid blood flow and the nasal bone in second-trimester screening for trisomy 21.
    Stressig R; Kozlowski P; Froehlich S; Siegmann HJ; Hammer R; Blumenstock G; Kagan KO
    Ultrasound Obstet Gynecol; 2011 Apr; 37(4):444-9. PubMed ID: 20645398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuchal fold thickness, nasal bone absence or hypoplasia, ductus venosus reversed flow and tricuspid valve regurgitation in screening for trisomies 21, 18 and 13 in the early second trimester.
    Geipel A; Willruth A; Vieten J; Gembruch U; Berg C
    Ultrasound Obstet Gynecol; 2010 May; 35(5):535-9. PubMed ID: 20183867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
    Kagan KO; Cicero S; Staboulidou I; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Mar; 33(3):259-64. PubMed ID: 19248005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.
    Alldred SK; Takwoingi Y; Guo B; Pennant M; Deeks JJ; Neilson JP; Alfirevic Z
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012600. PubMed ID: 28295158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing.
    Kagan KO; Staboulidou I; Cruz J; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2010 Nov; 36(5):542-7. PubMed ID: 20503223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
    Kagan KO; Valencia C; Livanos P; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Jan; 33(1):18-22. PubMed ID: 19031473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
    Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
    Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved diagnostic accuracy by using secondary ultrasound markers in the first-trimester screening for trisomies 21, 18 and 13 and Turner syndrome.
    Karadzov-Orlic N; Egic A; Milovanovic Z; Marinkovic M; Damnjanovic-Pazin B; Lukic R; Joksic I; Curkovic A; Mikovic Z
    Prenat Diagn; 2012 Jul; 32(7):638-43. PubMed ID: 22570267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K; Nicolaides KH
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prenatal sonographic features of fetuses in trisomy 13 pregnancies. IV.
    Chen CP
    Taiwan J Obstet Gynecol; 2010 Mar; 49(1):3-12. PubMed ID: 20466286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
    Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended first-trimester screening using multiple sonographic markers and maternal serum biochemistry: a five-year prospective study.
    Hsiao CH; Cheng PJ; Shaw SW; Hsu JJ; Chen RC; Tseng YJ; Chu WC
    Fetal Diagn Ther; 2014; 35(4):296-301. PubMed ID: 24503519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 103.